Small Intestinal Bacterial Overgrowth (SIBO)

Key Points

• SIBO denotes excessive or abnormal bacterial colonization of the small intestine causing symptoms and/or malabsorption.
• Jejunal/duodenal aspirate with quantitative culture is the historical gold standard; thresholds vary (classically >10^5 CFU/mL; some centers use ≥10^3 CFU/mL).
• Glucose and lactulose breath tests are noninvasive diagnostic tools; hydrogen and methane measurements have distinct interpretations (H2 rise for SIBO, methane for intestinal methanogen overgrowth/IMO).
• Treat underlying anatomic/motility drivers, correct nutritional deficiencies, and use targeted antibiotic regimens; rifaximin is commonly used for hydrogen‑predominant SIBO and combined regimens for methane‑predominant disease.
• Recurrence is common (~30–40%); strategies include repeat/rotating antibiotics, prokinetics, dietary measures, and addressing causative anatomy or motility disorders.

I. Definition and Epidemiology

Definition

SIBO is excessive bacterial colonization of the small intestine by organisms more typical of the colon and/or increased total bacterial load in the small bowel lumen, producing symptoms and sometimes malabsorption.

Prevalence and at‑risk groups

• Exact prevalence varies by population and diagnostic method; SIBO is more common in patients with structural or motility abnormalities and in those on long‑term acid suppression.
• Common predisposing conditions:
  • Motility disorders (intestinal pseudo‑obstruction, chronic intestinal dysmotility, diabetic autonomic neuropathy)
  • Anatomic abnormalities (short‑bowel syndrome, blind loops, strictures, adhesions, bypassed segments, resection of ileocecal valve)
  • Pancreatic insufficiency and chronic pancreatitis
  • Cystic fibrosis
  • Long‑term proton pump inhibitor (PPI) use causing hypochlorhydria
  • Immune deficiency states
  • Post‑surgical anatomy and bowel stasis
• Motility disorders and chronic pancreatitis together account for the majority of cases in clinic series.

II. Pathophysiology

• Normal gut microbiology: many species concentrated in distal small intestine and colon; stomach and proximal duodenum have low bacterial counts due to acid and motility.
• Physiologic defenses preventing SIBO:
  • Chemical: gastric acid, bile salts, pancreatic enzymes, mucosal immunity
  • Mechanical: migrating motor complex (MMC), antegrade peristalsis, intact ileocecal valve
  • Mucosal barrier and resident immune cells
• Disruption of any defense (hypochlorhydria, motility loss, anatomic stasis, enzyme deficiency, immune dysfunction) predisposes to overgrowth.
• Microbial effects causing symptoms and malabsorption:
  • Bacterial deconjugation of bile acids → fat malabsorption and fat‑soluble vitamin deficiencies
  • Bacterial fermentation of carbohydrates → excess H₂, CH₄, CO₂ and symptoms of bloating, flatulence
  • Competition for vitamin B12 and ileal inflammation → B12 deficiency
  • Bacterial protein degradation → ammonia production; in severe cases contributes to encephalopathy
  • Gram‑negative endotoxin release can contribute to systemic inflammation and cholestasis in susceptible patients
• Mucosal changes may include lamina propria inflammation, villous blunting, erosions or ulcers in severe disease.

III. Clinical Manifestations

• Typical symptoms: bloating, increased flatus, abdominal discomfort/cramping, early satiety, dyspepsia.
• Diarrhea (watery) is common; steatorrhea occurs when significant fat malabsorption is present (often with altered anatomy).
• Weight loss, failure to thrive (pediatrics), and signs of micronutrient deficiency (B12 neuropathy, vitamin D deficiency, hypocalcemia) occur in severe or chronic SIBO.
• D‑lactic acidosis (D‑lactate encephalopathy) is a rare complication in settings with carbohydrate malabsorption and colonic flora overgrowth, presenting with ataxia, slurred speech, confusion.
• Some patients are asymptomatic despite abnormal test results; correlate clinically before treating.
• Physical exam may show abdominal distension, increased bowel sounds/borborygmi, surgical scars, or peripheral edema from hypoalbuminemia in severe cases.

IV. Differential Diagnosis

• Irritable bowel syndrome (IBS)
• Lactose or other carbohydrate malabsorptions
• Celiac disease
• Chronic pancreatitis
• Giardiasis or other infectious enteritides
• Motility disorders

V. Diagnosis

Overview

Diagnosis uses clinical assessment, laboratory evaluation for malabsorption/nutrient deficiencies, microbiologic testing (jejunal aspirate), and breath testing (hydrogen and methane). Each modality has strengths and limitations; interpret tests in the clinical context.

Laboratory evaluation

• Complete blood count: anemia (macrocytic with B12/folate deficiency; microcytic with iron deficiency from bleeding or malabsorption)
• Vitamin B12, folate, iron studies, fat‑soluble vitamins (A, D, E, K)
• Metabolic panel including calcium, liver tests for cholestasis/IFALD
• D‑lactate when encephalopathy suspected; D‑lactate >3 mmol/L may support diagnosis
• Stool studies for fat (fecal fat), and infectious studies if indicated

Jejunal/duodenal aspirate and culture (gold standard)

• Technique: endoscopic aspiration of proximal small intestinal fluid (duodenal or jejunal) with quantitative culture.
• Interpretation thresholds:
  • Classic diagnostic cutoff: >10⁵ CFU/mL.
  • Some centers and recent studies use a lower threshold such as ≥10³ CFU/mL; be familiar with local lab standards.
• Limitations: invasive; risk of contamination with oropharyngeal flora; patchy distribution of bacteria may produce sampling error; not widely available in all centers.

Breath testing (noninvasive)

• Substrates: glucose or lactulose are commonly used for SIBO testing; lactose or fructose used to test specific sugar malabsorption.
• Mechanism: bacterial fermentation of substrate produces H₂ and/or CH₄ measured in expired breath; CO₂ measured to ensure alveolar sampling quality.
• Sampling: baseline then every 15 minutes for 2–4 hours depending on protocol.
• Preparatory instructions (to minimize false results):
  • Avoid antibiotics for 4 weeks prior to testing.
  • Hold prokinetics and laxatives for 1 week before the test.
  • Fasting 8–12 hours prior; avoid complex carbs and dairy for 12 hours before test.
  • No smoking or strenuous exercise on test day.
• Interpretation (commonly used cutoffs):
  • Hydrogen: rise in H₂ >20 ppm above baseline within 90 minutes (or within 60–90 min depending on protocol) is considered diagnostic of SIBO by many centers.
  • Methane: CH₄ ≥10 ppm at any time during the test suggests intestinal methanogen overgrowth (IMO); methane is associated with constipation‑predominant symptoms.
  • Baseline H₂ >20 ppm suggests poor adherence to preparation or baseline fermentation.
• Limitations and pitfalls:
  • Glucose breath test: good specificity for proximal SIBO but can miss distal overgrowth; sensitivity reported variably (wide ranges).
  • Lactulose breath test: may detect distal overgrowth and small intestinal transit abnormalities but is susceptible to false positives from rapid transit to colon; sensitivity and specificity vary widely across studies.
  • False negatives occur when organisms do not produce H₂ or when breath testing methodology is suboptimal.
  • Interpretation must consider clinical pretest probability, symptoms, and potential confounders (rapid transit, short bowel, recent antibiotics).

VI. Management

Principles

• Treat symptoms and malabsorption; correct micronutrient deficiencies.
• Address underlying cause (restore motility, correct anatomy, treat pancreatic insufficiency, review and stop PPIs if appropriate).
• Use targeted antibacterial therapy to reduce overgrowth; consider nonantibiotic adjuncts (prokinetics, dietary interventions, probiotics) and nutritional support when needed.

Antibiotic therapy

Antibiotics are the mainstay of initial therapy. Specific agents and regimens should be individualized by local practice, patient age, comorbidities, and microbial phenotype (hydrogen vs methane predominance).

Duration: 7–14 days is common for initial therapy; longer or repeated courses may be needed for refractory or recurrent disease. Pediatric dosing and safety considerations require specialist input.

Non‑antibiotic strategies

• Prokinetics (e.g., low‑dose erythromycin, prucalopride, metoclopramide where appropriate) can improve small bowel clearance and reduce recurrence in motility disorders.
• Dietary approaches:
  • Low‑FODMAP diets or lactose restriction may provide symptomatic relief but evidence specific to SIBO is limited.
  • Elemental diet (short course, e.g., 2 weeks) can reduce bacterial load and is an option for patients intolerant of or refractory to antibiotics.
• Probiotics: small studies suggest possible benefit in adults but data are inconsistent; no definitive pediatric guidelines — consider on case‑by‑case basis.
• Stop or minimize PPIs when clinically feasible to reduce hypochlorhydria‑related risk.

Addressing underlying problems

• Surgical correction of blind loops, strictures, fistulae, or other anatomic causes when appropriate.
• Optimize pancreatic enzyme replacement therapy in pancreatic insufficiency.
• Intestinal transplant referral for severe, refractory short‑bowel patients with unresolvable complications (rare, specialized pathway).

Managing complications and deficiencies

• Replace vitamin B12 (intramuscular or high‑dose oral depending on severity), fat‑soluble vitamins, iron, and other micronutrients as indicated.
• Treat D‑lactic acidosis with carbohydrate restriction and repletion strategies; consider empiric antibiotics while addressing gut flora and nutrition.
• Monitor and correct electrolyte and protein losses in patients with high stoma/intestinal output.

VII. Recurrence and Long‑term Management

• Recurrence or persistence of symptoms occurs commonly; clinical series suggest ~30–40% recurrence rates after initial therapy.
• Approach to recurrence:
  • Early recurrence (<3 months): empiric repeat antibiotic course, often with a different agent or combination.
  • Late recurrence (>3 months): re‑evaluate with breath testing or aspirate as clinically indicated; reassess for underlying causes and consider long‑term/rotating antibiotic strategies or adjunctive measures (prokinetics, elemental diet).
• For refractory or frequently recurrent SIBO: consider motility testing (manometry, wireless motility capsule), surgical review for anatomic causes, and multidisciplinary management.

VIII. Special Populations

Pediatrics

• Presentation: failure to thrive, feeding intolerance, abdominal distension, and similar GI symptoms; testing and dosing require pediatric expertise.
• Jejunal aspirate may be technically challenging in small children; breath tests can be used with pediatric protocols and adjusted substrates/doses.
• Antibiotic dosing must be weight‑adjusted and consider safety; many antibiotic regimens used in adults have pediatric equivalents but consult pediatric infectious disease or gastroenterology.

Patients with altered anatomy or short‑bowel syndrome

• High pretest probability of SIBO; breath tests may be confounded by rapid transit or altered anatomy; aspirate culture can be useful when feasible.
• Management often requires combined surgical, nutritional, and antimicrobial strategies; recurrent SIBO may contribute to difficulty weaning PN.

Immunocompromised patients

• Higher risk for severe infection and complications; tailor diagnosis and therapy with infectious disease involvement.

IX. Endoscopy and Histology

• Most patients have normal mucosa on endoscopy.
• Severe cases may show mucosal edema, loss of vascular pattern, patchy erythema, friability, ulceration, eosinophilia, villous blunting, intraepithelial lymphocytosis, or cryptitis.
• Endoscopic biopsies help exclude alternative diagnoses (celiac disease, inflammatory bowel disease, eosinophilic enteritis) and identify inflammatory or ulcerative mucosal changes when present.

X. Outcomes and Prognosis

• Many patients experience symptomatic improvement after a course of appropriate antibiotics, but relapse is common.
• Long‑term prognosis depends on underlying etiology (motility disorder, anatomic cause, pancreatic insufficiency) and ability to correct predisposing factors.
• Severe, chronic SIBO with malabsorption can lead to persistent nutritional deficits, metabolic bone disease, and growth failure in children if not addressed.

XI. Evidence Gaps and Research Directions

• Need for standardized breath test protocols (substrate, timing, cutoffs) and uniform diagnostic thresholds for aspirate cultures.
• Comparative randomized trials of antibiotic regimens, optimal durations, and strategies for recurrent SIBO are limited.
• Role of probiotics, microbiome‑directed therapies, dietary strategies (low‑FODMAP), and nonantibiotic agents needs higher‑quality pediatric and adult data.

XII. Practical Appendix

Breath test preparation and protocol (common practical checklist)

• Avoid antibiotics for 4 weeks prior to testing.
• Hold prokinetics and laxatives for 1 week before testing if clinically safe.
• Fast 8–12 hours before test; avoid complex carbs and dairy for 12 hours.
• No smoking or strenuous exercise on test day.
• Collect baseline sample; administer substrate (typical examples: 75 g glucose or 10 g lactulose); collect samples every 15 minutes for 2–4 hours depending on protocol.
• Measure H₂, CH₄, and CO₂ (to confirm alveolar sampling quality).

Interpreting breath tests (practical rules)

• H₂ rise >20 ppm above baseline within 60–90 minutes commonly used to indicate SIBO.
• CH₄ ≥10 ppm at any time indicates intestinal methanogen overgrowth (IMO) and is associated with constipation.
• Baseline H₂ >20 ppm suggests inadequate preparation or baseline fermentation; interpret cautiously.
• Consider transit time and clinical context; correlate with symptoms and labs.

Common antibiotic regimens (adult dosing examples — adjust for pediatrics)

Rifaximin 550 mg orally three times daily for 14 days (hydrogen‑predominant)
Rifaximin 550 mg TID + Neomycin 500 mg BID for 14 days (methane‑predominant / IMO)
Metronidazole 500 mg TID for 7–14 days (alternative)
Amoxicillin‑clavulanate or TMP‑SMX per local practice and susceptibility
Elemental diet (2 weeks) as alternative for refractory cases
  

Aminoglycosides (neomycin) carry risk of nephrotoxicity and ototoxicity; use cautiously and monitor. Pediatric doses require weight‑based adjustment and specialist input.

XIII. Suggested Practical Algorithm (concise)

1. Assess symptoms, risk factors, and baseline labs (B12, folate, iron, LFTs, albumin).
2. If high pretest probability and noninvasive testing feasible: perform breath test with glucose or lactulose per protocol.
3. If breath test positive (H₂ rise or methane ≥10 ppm) and clinical correlation present: begin targeted therapy (antibiotics ± adjuncts) and correct deficiencies.
4. If breath test negative but strong clinical suspicion, or if breath test inconclusive and management decisions depend on definitive diagnosis: consider jejunal aspirate/culture or empiric therapy with careful follow‑up.
5. For recurrence: reassess for underlying cause, consider repeat testing, and treat with alternative or rotating antibiotics; add prokinetics/dietary strategies and review need for surgical correction if anatomy involved.